Fast Market Research announces the availability of the new TechNavio report, "Global MRSA Drugs Market 2016-2020", on their comprehensive research portal

Boston, MA -- (SBWire) -- 08/23/2016 --MRSA is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly-used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of Staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin.

Technavio's analysts forecast the global MRSA drugs market to grow at a CAGR of 1.34% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global MRSA drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent MRSA infections.

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global MRSA Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Get More Details on this Report and a Full Table of Contents at Global MRSA Drugs Market 2016-2020

Key vendors

-Allergan
-Merck & Co.
-Pfizer
-Theravance Biopharma

Other prominent vendors

-Absynth Biologics
-AmpliPhi Biosciences Corporation
-AstraZeneca
-Basilea Pharmaceutica
-Baxter International
-Cellceutix
-Cempra Inc.
-CrystalGenomics
-Debiopharm Group
-Galapagos NV
-GSK
-KYORIN Pharmaceutical
-Lytix Biopharma
-Melinta Therapeutics
-Nabriva Therapeutics
-NovaDigm Therapeutics
-Paratek Pharmaceuticals
-R-Pharm
-Savara Pharmaceuticals
-Sealife Pharma
-Sequella Inc.
-The Medicines Company
-XBiotech

Market driver

-Special regulatory designations
-For a full, detailed list, view our report

Market challenge

-Development of drug-resistant strains
-For a full, detailed list, view our report

Market trend

-Strategic alliances and M&A
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2020 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Allergan, , Merck, , Pfizer, , Theravance, , Absynth Biologics, , AmpliPhi Biosciences, , AstraZeneca, , Basilea Pharmaceutica, , Baxter International, , Cellceutix, , Cempra, , CrystalGenomics, , Debiopharm, , Galapagos NV, , GSK, , KYORIN Pharmaceutical, , Lytix Biopharma, , Melinta Therapeutics, , Nabriva Therapeutics, , NovaDigm Therapeutics, , Paratek Pharmaceuticals, , R-Pharm, , Savara Pharmaceuticals, , Sealife Pharma, , Sequella, , The Medicines Company, , XBiotech.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:
-PharmaPoint: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Market Analysis to 2024
-Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024
-Methicillin-Resistant Staphylococcus aureus (MRSA) - US Drug Forecast and Market Analysis to 2024
-Methicillin-Resistant Staphylococcus aureus (MRSA) - Japan Drug Forecast and Market Analysis to 2024
-Global Solid Tumors Drugs Market 2016-2020